Transplantation for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow
NCT02757885
Completed
The purpose of this study is to learn if it is possible and safe to treat persons with severe sickle cell disease (SCD) by bone marrow transplant (BMT) from human leukocyte antigen (HLA) half-matched related donors. Preparation before transplant includes the chemotherapy drugs hydroxyurea, fludarabine, thiotepa, anti-thymocyte globulin, and cyclophosphamide. It also includes radiation.
Gender:
ALL
Ages:
Between 15 years and 40 years
Trial Updated:
09/19/2023
Locations: Children's Healthcare of Atlanta, Atlanta, Georgia
Conditions: Sickle Cell Disease
Register for Updates
FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
NCT04551885
Terminated
This is a Phase 1 dose-finding study of FT-516 in combination with monoclonal antibodies in participants with advanced solid tumors. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/19/2023
Locations: University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota +2 locations
Conditions: Solid Tumor, Adult
Register for Updates
FT538 in Subjects With Advanced Hematologic Malignancies
NCT04614636
Terminated
This is a Phase I dose-finding study of FT538 as monotherapy in acute myeloid leukemia (AML) and in combination with monoclonal antibodies in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/19/2023
Locations: Colorado Blood Cancer Institute, Denver, Colorado +7 locations
Conditions: Acute Myeloid Leukemia, AML, Adult, Multiple Myeloma, Myeloma
Register for Updates
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
NCT05069935
Terminated
This is a Phase 1 dose-finding study of FT538 in combination with monoclonal antibodies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/19/2023
Locations: Hackensack University Medical Center, Hackensack, New Jersey +3 locations
Conditions: Solid Tumor, Adult
Register for Updates
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
NCT05395052
Terminated
This is a Phase 1 dose-finding study of FT536 given in combination with a monoclonal antibody following lymphodepletion in participants with advanced solid tumors. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/19/2023
Locations: Honor Health Research Institute, Scottsdale, Arizona +4 locations
Conditions: Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, GastroEsophageal Cancer
Register for Updates
Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders
NCT05293509
Withdrawn
To assess the outcomes of NRM when administering pharmacologic pretransplant immunosuppression (PTIS) followed by pretransplant reduced toxicity conditioning (RTC) and an allogeneic stem cell transplant (allo-SCT) and post-transplant graft-versus-host disease prophylaxis based on post-transplant cyclophosphamide (PT-Cy) in patients with inherited blood disorders.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/18/2023
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Stem Cell Transplantation
Register for Updates
A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma
NCT04171843
Terminated
This is a Phase 1/2a, nonrandomized, open-label, parallel assignment, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR269A, with or without nirogacestat, in adults with r/r MM. Study subjects in Cohort A will receive PBCAR269A and study subjects in Cohort B will receive PBCAR269A and nirogacestat. At each dose level, study subjects in Cohort A and Cohort B will receive the same dose of PBCAR269A. In Cohort B, all study subjects will fol... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/18/2023
Locations: City of Hope, Duarte, California +4 locations
Conditions: Relapsed/Refractory Multiple Myeloma
Register for Updates
Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
NCT01336933
Completed
This phase II trial studies how well combination chemotherapy and pralatrexate works in treating patients with non-Hodgkin lymphoma (NHL). Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/13/2023
Locations: Mayo Clinic, Arizona, Scottsdale, Arizona +8 locations
Conditions: Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Peripheral T-cell Lymphoma
Register for Updates
Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Who Have Undergone Surgery
NCT01106898
Completed
This phase II trial studies the side effects and how well giving cyclophosphamide and paclitaxel with or without trastuzumab works in treating patients with stage I-II breast cancer who have undergone surgery. Drugs used in chemotherapy, such as cyclophosphamide and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving monoclonal antibody therapy, such as trastuzumab, with chemotherapy may kill more tumor cells... Read More
Gender:
FEMALE
Ages:
20 years and above
Trial Updated:
09/13/2023
Locations: Saint Francis Medical Center, Grand Island, Nebraska +1 locations
Conditions: Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer
Register for Updates
Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)
NCT00499083
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, cyclophosphamide, and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Injecting the patient's dendritic cells directly into the tumor may stimulate the immune system and stop tumor cells from growing. Radiation therapy uses high-energy x-rays to kill tumor cells. Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen may f... Read More
Gender:
FEMALE
Ages:
Between 19 years and 120 years
Trial Updated:
09/13/2023
Locations: H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida +1 locations
Conditions: Breast Cancer
Register for Updates
Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer
NCT01873833
Terminated
This phase II trial studies how well capecitabine, cyclophosphamide, lapatinib ditosylate, and trastuzumab work in treating patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. Drugs used in chemotherapy, such as capecitabine and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving capecitabine and cyclophosphamide daily may kill more tumor cells. Lapatinib dit... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/12/2023
Locations: USC Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Register for Updates
Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)
NCT00562640
Completed
RATIONALE: Giving colony-stimulating factors, such as G-CSF, helps stem cells move from the bone marrow to the blood so they can be collected. Treating stem cells collected from the patient's blood in the laboratory may increase the number of immune cells that can mount an immune response against the tumor. The treated stem cells may help destroy any remaining tumor cells (graft-versus-tumor effect). Chemotherapy may also be given to the patient to prepare the bone marrow for the stem cell trans... Read More
Gender:
FEMALE
Ages:
Between 18 years and 120 years
Trial Updated:
09/11/2023
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Register for Updates